Rapigen Secures WHO Prequalification for Three pLDH-Based Malaria Rapid Diagnostic Tests
Rapigen has announced that it has secured WHO prequalification for three of its pLDH-based malaria rapid diagnostic tests. This milestone indicates that these tests meet the World Health Organization’s standards for quality, safety, and efficacy.
NY, UNITED STATES, April 24, 2026 /EINPresswire.com/ — pLDH-Based Diagnostic Technology Addresses Growing Threat of HRP2 Gene Deletions — Enabling Expanded Access to Global Malaria Diagnostics Markets
Rapigen, Inc., an in vitro diagnostics company …